Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER3 inhibitors

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Electronic medical records ‘could boost clinical trial efficiency’

Quicker recruitment times and lower development costs among potential benefits, says Parexel

- PMLiVE

FDA turns down tivozanib for kidney cancer

Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable"

- PMLiVE

GSK fires senior Chinese scientist over data fabrication

Pharma company dismisses head of Chinese R&D unit after tip-off about inaccurate MS data in journal

- PMLiVE

Ben Goldacre: No escape from trial transparency

Bad Pharma author says AllTrials and new European legislation make data disclosure unavoidable

- PMLiVE

­Pfizer signs $635m deal with CytomX for cancer ADCs

Will use biotech's Probody technology to develop antibody-drug conjugates

- PMLiVE

JWT Brazil devises superhero theme for paediatric oncology patients

Agency draws on Warner Bros characterisation to make treatment more child-friendly

- PMLiVE

Mirna hires former Pfizer director as CMO

Dr Sinil Kim has extensive experience in oncology

- PMLiVE

Regulatory struggles force Aveo to cut 140 jobs

Expects FDA rejection for tivozanib in kidney cancer

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

Alexza’s Peter Schineller joins Agendia

Appointed first chief commercial officer

- PMLiVE

ASCO: Amgen says viral therapy for melanoma “encouraging”

T-VEC is potential advancement in skin cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links